A2AR  ➣ Antagonists:
ZM241385 (38, 54)
ZM241365 (389)
SCH58261 (54, 292, 384, 392–394)
FSPTP (395)
CPI-444 (396)
PBF-509 (397)  ➣ Breast:
4T1.2 (292)
➣ Melanoma:
B16-F10 (292, 384, 389, 394, 395, 397)
CL8-1 (38)
BRAFV600E-PTEN-deficient mice (393)
LWT1 (393)
➣ Colon:
CT26 (396)
MC38 (396)
➣ NSCLC: PC9a (54)
➣ Bladder: MB49 (395)
➣ HNSCC: Tgfbr1/Pten double KO (392)
➣ Fibrosarcoma: MCA205 (397)  ➣ Primary tumor expansion rate ↓ (38, 54, 389, 392, 393, 396)
T cells (38)
Retained in NUDE micelackingT cells (54)
➣ Metastasis formation ↓ (292, 384, 393, 394, 397)
Tumor CD73 (292, 394)
Host A2AR (292)
T cells, B cells or NK cells (292)
Perforin (292)
➣ Survival↑ (384, 396)
CD8 T cells > NK cells (394)  ↓ CD8+, CD4+ T cells (395)↑ CD8+ T cells (389, 392, 393)↑ CD69 on CD8+ T cells (393)↓ A2AR+ CD8+ T cells (392)↑ IFN-γ+ CD8+ T cells (392)↑ T-bet, 41-BB in/on CD44+CD8+ T cells (396)↑ IFN-γ, TNF-α production by CD8+ T cells (392)↑ stimulation-induced IFN-γ/TNF-αproduction by CD8+ T cells (396)↑ NK cells (393, 395)↑ GzB+ NK cells (292)↓ Tregs (389, 392, 393)↓ PD-1, LAG3, FOXP3 on Tregs (396)↓ A2AR+ Tregs (392)↓ FOXP3 (392)